Abstract 8P
Background
Tumor metabolism and tumor-specific immune responses are one of integral compartments consisting of tumor niche. Several lines of evidence showed that tumor cells and tumor-infiltrating lymphocytes (TILs) compete for glucose in tumor microenvironment and that tumor metabolic parameter correlates with localized immune markers in several solid tumors. With this background, we compared standardized uptake value (SUV) of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET-CT) and stromal TILs in breast cancer (1≥cm).
Methods
Two hundred two patients were identified among those who underwent preoperative 18F-FDG-PET-CT and had tumor size equal to or larger than 1cm. Maximum SUV was obtained from 18F-FDG-PET-CT. Stromal TILs was evaluated according to standardized methodology proposed by the international TIL Working Group. We identified factors related with high TILs (≥40%) using multiple logistic-regression. All tumors were treatment-naïve.
Results
There was a significant but weak correlation between continuous SUV and continuous TILs (p = 0.002, R = 0.215). Mean TILs was significantly high in Ki-67 labeling index ≥14%, nuclear/histologic grade 3, and HER2-positive or triple-negative breast cancer (TNBC). In multivariable analysis, aggressive subtypes as HER2-positive or TNBC and continuous SUV were significantly associated with high TILs ≥40%.
Conclusions
We found that SUV was associated with TILs in breast cancer and provide clinical evidence that elevated glucose uptake of breast tumors may be affected by TILs in tumor micromileu.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract